Considerable evidence suggests that pro-inflammatory pathways drive self-renewal of cancer stem-like cells (CSC), but the underlying mechanisms remain mainly undefined.
Introduction
Tumor-promoting inflammation has been recognized as one of the hallmarks of cancer (1) . NF-κB activation is one of the pillars of inflammation which provides a mechanistic link between inflammation and cancer (2, 3) . In fact, it is known that the IKKβ-dependent NF-κB activation pathway provides a critical molecular link between inflammation and colon cancer growth in mouse models (4, 5) and that the specific inhibitor for IKKβ shows promising antineoplastic effects (6) (7) (8) . Cancer stem cells (CSCs) are highly tumorigenic, relatively resistant to conventional chemotherapy and radiotherapy and involved in both tumor initiation and metastasis (9, 10) . It has been proposed that the development of more effective cancer therapies may require specific targeting of the CSCs population. Several studies have also revealed that the NF-κB pathway plays critical roles in sustaining the stemness of CSCs (11, 12) and that targeting this pathway impairs self-renewal of CSCs (8) ; however, the molecular mechanisms by which NF-κB regulates CSCs are not fully understood. Wnt/β-catenin signaling controls virtually every aspect of embryonic development and mediates homeostatic self-renewal in adult tissues (13, 14) . Recent studies have demonstrated the essential role of transcriptional factor TCF7L2 in adult intestinal homeostatic self-renewal and oncogenic program (15) (16) (17) . It is worth noticing that a recent study has revealed that interaction between NF-kB and Wnt signaling promotes tumor-initiating cells traits during intestinal tumorigenesis (18) . miRNAs (19, 20) . Thus, repression of let-7 is important in establishing the pluripotent state of embryonic stem cells. Several reports also indicate that LIN28 can affect protein levels by regulating mRNA stability and modulate cell proliferation by enhancing translation of various cell-cycle regulators in murine embryonic stem cells (21, 22) . Therefore, LIN28 may promote reprogramming through both miRNA-dependent and independent pathways. In fact, it has been reported that LIN28A/LIN28B can promote transformation by repressing let-7 miRNAs, and that activation of LIN28A/LIN28B occurs in many different human tumors with a frequency of ~15% (23, 24) . Recent studies have also suggested that LIN28 plays an important role in the maintenance of CSCs (25, 26) and Wnt signaling could directly activate LIN28 to augment breast cancer stem cell expansion (27) .
This study aims to obtain evidences that LIN28B and TCF7L2 are the key molecular players that mediate the function of NF-κB signaling in CSCs and to identify a novel molecular mechanism by which the LIN28B/TCF7L2 interaction loop, when activated by IKKβ, sustains the stemness of CSCs to promote cancer progression and metastasis.
Materials and Methods

Cell lines and reagents
The human breast cancer cell lines MDA-MB-231 and MCF-7, NSCLC cell line 
Immunohistochemistry
The tissue microarray used for analysis of the correlation of LIN28B expression with stemness markers and clinical stages of breast cancer were purchased from Alenabio Inc.
(Xi'an, China). The tissue microarray used for analysis of the correlation of LIN28B expression with survival of patients with breast or lung cancer was purchased from Shanghai Outdo Biotech (Shanghai, China). The pictures of immunohistochemistry were captured by microscope (Leica, Germany). The expression level of LIN28B was based on the proportion of positive cancer cells of 5 random fields in the tissues and the cut off defined as low (0-30%), mediate (30-60%) or strong (60-100%) expression of LIN28B.
Tyramide Signal Amplification (PerkinElmer, Inc. Waltham, MA) was used for tissue immunofluorescence. Cy3, Cy5 and FITC-conjugated second antibody (Sigma) was used to visualize LIN28B, ALDH1 and OCT4 respectively in immunofluorescence assay. The pictures of immunofluorescence were captured by confocal (Olympus, Japan).
Flow cytometry
The ALDEFLUOR assay (Stemcell Technologies) was performed according to the manufacturer's guidelines to identify cells with high ALDEFLUOR activity. Cells were incubated for 40 minutes at 37°C in the presence or absence of the ALDH inhibitor 
Tumorsphere assay
Single cell suspensions were seeded in 6-well or 24-well ultra-low attachment plates (Corning) in sphere-culturing medium (Stemcell Technologies) for 7-14 days. For limited dilution assays, MDA-MB-231 cells were plated (after sorting) at 1, 10, 100, 1000 cells/well or H1299 cells were plated (after sorting) at 10, 100, 1000, 10000 cells/well in 24 wells (6 wells/condition). The number of wells with spheres was recorded on day 14 after culturing. Tumorsphere formation was monitored using an inverted Leica microscope fitted with a camera. Data analysis performed using the publically available ELDA software as detailed in reference (29) . Secondary tumorspheres were obtained following the mechanical and enzymatic dissociation of primary tumorspheres as described previously (30) .
RNAi experiment
RELA, RELB, IKKβ, LIN28B or TCF7L2 siRNA was transiently transfected using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. selected with puromycin (2 μg/ml). After a week cell pools were obtained and expanded.
Western blotting
Cells were lysed in protein extraction reagent (Pierce) and loaded onto NuPAGE gels (Invitrogen). Blots were incubated with the respective primary antibody diluted in TBST (containing 0.1% Tween 20 and 5% BSA) overnight at 4 °C. Then, blots were washed and incubated with appropriate secondary antibodies (Santa cruze) and detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce). The band intensities in Western blotting were quantified with the LAS4000 Image Analyzer.
Luciferase assay
The Cignal Finder Reporter Array (Qiagen) was used to identify the signaling 
Animal study
Female NOD/SCID mice, 6-8 weeks of age, were purchased from Vital River 
Statistical analysis
All results were presented as the standard error of the mean (SEM). Table 4 ). It was also found by IHC staining that LIN28B expression was associated with ALDH1 and SOX2, two stemness markers. (Fig. 1B, Supplementary Fig. 1A , Supplementary Table 5, 6). These results were extended by immunofluorescence staining which indicated that LIN28B expression was correlated with OCT4 and ALDH1 expression (Fig. 1C) . Furthermore, statistical analysis revealed that higher LIN28B level was associated with shorter overall survival of patients with either breast cancer (n= 159; 5A ). As expected, low expression of LIN28B reduced the expression of stemness related genes including SOX2, OCT4 and NANOG in MDA-MB-231 and H1299 cells ( Fig. 2A) .
Moreover, we also found that low expression of LIN28B reduced the proportion of ALDH + cells ( Table 12 ). Moreover, pulmonary metastasis in groups of mice with reduced LIN28B was clearly suppressed as indicated by PET scan and H&E staning analysis (Fig. 2G, H, Supplementary Fig. 5F ). Together Fig. 2A, B) . We also used human macrophages THP1, which were treated with PMA and TH2 cytokines to induce M2 phenotype macrophages as TAMs (34) that were co-cultured with MDA-MB-231 and MCF-7 cells (Supplementary Fig. 3A ). It Fig. 3D ). Moreover, cell surface marker CD44 was up-regulated in MCF-7 cells when co-cultured with THP1 cells by Flow Cytometry (Supplementary Fig. 3E ). These results suggest that ALDH + cells had CSCs properties, and that the inflammatory tumor microenvironment could activate IKKβ to enhance tumor stemness properties in cancer cells.
NF-κB was shown to be important in TICs isolated from HER2 + breast cancer (35) .
Based on this fact, we investigated how NF-κB activation was involved in the maintenance of stemness in breast cancer cells. Initially, we found the expressions of p-IKKβ and LIN28B were much higher in ALDH + of MDA-MB-231 and H1299 cells (Fig. 3A) . We then defined the factor in the NF-κB signaling pathway that played a leading role in this process. To this end, the main molecules in the NF-κB signaling (Fig. 3C) , the frequency of tumorsphere (Fig. 3D, Supplementary Table 11 ) and invasion ability (Fig. 3E) Fig. 6C-F) .
Furthermore, an in vivo experiment was performed to verify our in vitro results (Fig.   3H ). The tumor volume was decreased in IMD-0354 group at the end of 7 weeks (Supplementary Fig. 8A ). However, there was no difference in body weight of mice after IMD-0354 treatment (Supplementary Fig. 8B ). Pulmonary metastases in groups of mice treated with IMD-0354 were fewer than those in control groups (Fig. 3I) . In fact, H&E staining of lung specimens indicated clearly that the number of metastatic foci in lung were much fewer in groups of mice subjected to IMD-0354 treatment (Fig. 3J) . These results proved that IKKβ in the NF-κB signaling pathway, which was activated by the TME such as TAMs, played a critical role in up regulating LIN28B and in sustaining cancer stemness properties in a MDA-MB-231 breast cancer model. 
IMD-0354 on MDA-MB-231 cells. The result showed clearly that Wnt/β-catenin signaling pathway was significantly inhibited by IMD-0354 (Fig. 4A) , suggesting a correlation between Wnt/β-catenin and NF-κB signaling. Western blot analyses further indicated that the expression of TCF7L2 (TCF4), a key transcription factor in the Wnt/β-catenin signaling pathway, was down-regulated by either IKKβ inhibitor IMD-0354 or siIKKβ , but not by siRELA or siRELB, in MDA-MB-231 and H1299 cells ( Fig. 4B; Supplementary Fig. 6B, C) . Furthermore, we investigated whether LIN28B could be regulated by TCF7L2. As expected, LIN28B expression was reduced by siTCF7L2 ( Fig. 4D, Supplementary Fig. 7A ) and LIN28B expression was correlated with TCF7L2 in breast cancer tissues (Fig. 5F, Supplementary Table 7) . A further in depth investigation indicated the mechanism underlying the important interaction between TCF7L2 and LIN28B. In this regard, PROMO software analysis identified two putative binding sites of TCF7L2E (one isoform of TCF7L2) in intron 1 of LIN28B gene which were respectively named site 1 (AGCAAAG) and site 2 (CTGTACT) (Fig. 4D ).
Chromatin immunoprecipitation (ChIP) found that only site 2 could be tested in the TCF7L2/DNA complex ( Fig. 4E; Supplementary Fig. 7B ). We then constructed 4 plasmids containing both site 1/site 2, site 1, site 2 or mutant site 2 separately. A Luciferase reporter assay revealed that only site 2 had transcriptional activity which was in accord with the result of our ChIP assay ( Fig. 4F; Supplementary Fig. 7C) . Moreover, the transcriptional activity of the plasmid containing both site 1 and site 2 was increased significantly when β-catenin was over expressed ( Fig. 4G; (Supplementary Fig. 7D ). Unexpectedly we observed an interesting fact that expression of TCF7L2, but not β-catenin, could be inhibited as well by shLIN28B (Fig. 5A) . It indicated that down-regulation of LIN28B could reduce luciferase activity of TOP-flash ( Fig. 5C ; Supplementary Fig. 7E ), as well as the expression of such TCF7L2 downstream genes as BCL2, CCND1 and MYC in MDA-MB-231 cells (Fig. 5D) . Furthermore, RNA immunoprecipitation (RIP) experiments showed that LIN28B could directly bind to the mRNA of TCF7L2 in both of MDA-MB-231 and H1299 cells (Fig. 5E ). The down expression of LIN28B decreased the expression of TCF7L2 in MDA-MB-231 cells that was also confirmed by immunofluorescence (Fig. 5B) . We therefore proposed that LIN28B protein binding with TCF7L2 mRNA occurred in the cytoplasm, a finding consistent with our prior data indicating that LIN28B protein appeared in both cytoplasm and nucleus in breast cancer tissues. Moreover, the expression of LIN28B and TCF7L2 was highly correlated in breast cancer tissues (Fig. 5F ). It is evident that TCF7L2, Fig. 6B; Supplementary Fig. 10A ). Results showed that tumor volumes of the original site of the tumor in combined treatment group were significantly smaller compared to those in the control group ( Fig. 6C; Supplementary Fig. 10B ).
Moreover, the degree of pulmonary metastasis in the IMD-0354 only group and the combined treatment group significantly reduced (Fig. 6D, E was found in 4T1 model ( Supplementary Fig. 10B) ; however, tumor metastases in the lungs of these mice in both MDA-MB-231 and 4T1 models were not decreased in the Taxol only group ( Fig. 6D-E; Supplementary Fig. 10C ). The proportion of ALDH + cancer stem cells in the IMD-0354 only group and the combined treatment group were reduced in both MDA-MB-231 and 4T1 models; however, it increased in the Taxol only group in both two cell models ( Fig. 6F; Supplementary Fig. 10D ). Furthermore, histological analyses revealed that this combination therapy strategy could suppress the expression of p-IKKβ, TCF7L2, LIN28B, ALDH1, SOX2 and NANOG in tumor tissues, which supported our hypotheses (Fig. 6G) . Taken together, these results suggest that blockade of IKKβ activation with IMD-0354 may be able to inhibit TCF7L2/LIN28B interaction, suppress cancer stemness properties, and reduce tumor metastasis.
Discussion
Our experiment showed that LIN28B was up-regulated by inflammatory factor IKKβ showed that LIN28B promoted tumor cell transformation (23, 24) and had a functional role in CSCs maintenance (25, 26) . Consistent with these findings, our experiment results showed that expression of LIN28B was highly positively correlated with tumor progress in human breast cancer patients, indicating that there were high levels of LIN28B in stage 3 patients with lymphatic metastasis of breast cancer. LIN28B was shown to be a powerful predictor of poor clinical outcome. Besides, LIN28B was also shown highly positively correlated with stemness markers (ALDH1, SOX2 and OCT4) in breast cancer tissues. As far as mechanism are conserved, we determined that selected blockade of IKKβ phosphorylation reduced the CSC population and LIN28B expression by using either siIKKβ or IKKβ inhibitor IMD-0354. In this regard, Iliopoulos and colleagues found that LIN28B was activated by RELA to promote cell transformation (23) . In contrast, results from our study indicated that RELA was not the only player in regulating LIN28B expression; instead, IKKβ did play a key role in our human breast and lung cancer model. Importantly, we noted that suppression of IKKβ can inhibit the activity of Wnt/β -catenin signaling and reduced the expression of TCF7L2 which was a Wnt/β -catenin effector. We identified for the first time that TCF7L2 directly bound to intron 1 of LIN28B and up regulated LIN28B expression. This finding suggests that LIN28B a novel direct downstream target gene of the Wnt/β -catenin pathway. Interestingly, a recent research revealed that LEF1, another effector of Wnt/β -catenin pathway, could activate LIN28A via direct binding to the LIN28A promoter (27) . This reports provided compelling evidence that both LIN28A and LIN28B were direct target genes of the 
Wnt/β -catenin pathway. Hence, our results suggest that IKKβ regulated LIN28B expression with TCF7L2 assistance. However, we unexpectedly discovered that LIN28B bound directly to mRNA of TCF7L2, thereby activating the Wnt/β-catenin signaling pathway. In this regard, it is well known that LIN28B plays analogic biological function due to their parallel structural domains (42) . In fact, they bind to the terminal loops of precursors of let-7 family miRNAs and block their processing into mature miRNAs.
Furthermore, another study reported that let-7-dependent effects of LIN28B may supersede let-7-independent effects on intestinal tissue growth (43). Therefore, our study revealed a novel let-7-independent mechanism of LIN28B in regulating the function of CSC.
The development of strategies to effectively target the CSC population needs to be extended to improve outcome of cancer therapy. Here we proposed such an approach, based on blocking the IKKβ kinase activation to eliminate CSCs. Meanwhile, we also designed a combination therapeutic strategy of IKKβ inhibitor IMD-0354 and the cytotoxic agent Taxol. We tested the effects of this treatment in NOD/SCID and BALB/c mice and found that IMD-0354 treatment inhibited tumor metastasis to lung. In fact, the CSCs population was significantly reduced by either IMD-0354 treatment alone or in combined therapy with Taxol. However, the CSCs population increased after Taxol treatment alone which was analogous with other studies (36, 37) . Moreover, we found that expression of TCF7L2, LIN28B, SOX2 and NANOG were all decreased in tumor tissues following the combination therapy. In fact, IMD-0354 did not result in any side effect in mice (Supplementary Fig. 8B ). Our results suggested that blocking inflammatory activation may represent a novel and effective strategy to target CSCs.
Based on two cancers model (breast cancer and lung cancer), this study propsoes a novel mechanism of the inflammatory gene IKKβ regulating stemness and identifying the TCF7L2/LIN28B loop as the pivotal molecular bridge connecting inflammation and stemness through their interaction with CSCs. This mechanism suggests a novel therapeutic strategy with clinical potential, i.e. blocking activation of inflammation which targets CSC and suppresses tumor metastasis (Fig. 7) . Reporter plasmid containing both site1/site2 and a β-catenin or control plasmid were co-transfected into MDA-MB-231 cells, and luciferase activity was detected. Error bars represent mean ± SD from 3 independent experiments. ***p<0.001. 
